Search

Your search keyword '"Cao, Yongge"' showing total 337 results
Start Over Author "Cao, Yongge"
337 results on '"Cao, Yongge"'

41. A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

Author

Chu Xiaoying, Jinsong Liu, Lihua Xu, Yongping Li, Hu Xuanxuan, Zhanqiu Diao, Li Meiqi, Wan Leyu, Hui Ye, Zhensheng Cao, Fengting Peng, Zihan Wang, and Cao Yongge

Subjects
cervical cancer, medicine.medical_treatment, Genetic enhancement, Pharmaceutical Science, Uterine Cervical Neoplasms, Apoptosis, Cell Cycle Proteins, 02 engineering and technology, 01 natural sciences, Targeted therapy, Drug Delivery Systems, International Journal of Nanomedicine, Cell Movement, Drug Discovery, Cationic liposome, Molecular Targeted Therapy, Original Research, Drug Carriers, Mice, Inbred BALB C, Chemistry, Temperature, Combination chemotherapy, General Medicine, antisense lncRNA of MDC1, 021001 nanoscience & nanotechnology, targeted therapy, Gene Expression Regulation, Neoplastic, Drug delivery, Female, RNA, Long Noncoding, 0210 nano-technology, Drug carrier, medicine.drug, Static Electricity, Biophysics, Mice, Nude, Bioengineering, 010402 general chemistry, Biomaterials, In vivo, Cations, Cell Line, Tumor, medicine, Animals, Humans, Particle Size, Adaptor Proteins, Signal Transducing, Cell Proliferation, Magnetic Phenomena, Organic Chemistry, oxaliplatin, 0104 chemical sciences, Oxaliplatin, Drug Liberation, Liposomes, Cancer research, magnetic thermosensitive cationic liposome
Abstract

Hui Ye,1,* Xiaoying Chu,1,* Zhensheng Cao,2,* Xuanxuan Hu,1,* Zihan Wang,2 Meiqi Li,1 Leyu Wan,2 Yongping Li,3 Yongge Cao,4 Zhanqiu Diao,2 Fengting Peng,2 Jinsong Liu,2 Lihua Xu5 1School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People’s Republic of China; 2School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People’s Republic of China; 3Department of Surgery, Chengdu Shuangliu District Maternal and Child Health Hospital, ChengDu, Sichuan, 610200, People’s Republic of China; 4Department of Stomatology, Haiyuan College, Kunming, Yunnan, 650106, People’s Republic of China; 5Department of General Medicine, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hui YeSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People’s Republic of ChinaEmail wmcyh@wmu.edu.cnLihua XuDepartment of General Medicine, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, ChinaEmail lihuaxu@wmu.edu.cnBackground: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer.Methods: Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined.Results: The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery.Conclusion: The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer.Keywords: magnetic thermosensitive cationic liposome, oxaliplatin, antisense lncRNA of MDC1, targeted therapy, cervical cancer

Published
2021

48. Alveolar Bone Density Reduction in Rats Caused by Unilateral Nasal Obstruction

Author

Liu Zhenhua, Fengting Peng, Zhensheng Cao, Wang Xue, Hu Xuanxuan, Zhanqiu Diao, Chu Xiaoying, Zihan Wang, Han Zhao, Cao Yongge, Hui Ye, and Lei Wang

Subjects
Male, medicine.medical_specialty, Bone density, Alveolar Bone Loss, receptor activator of nuclear factor-κb ligand, lcsh:Medicine, nasal obstruction, Polymerase Chain Reaction, Bone remodeling, Rats, Sprague-Dawley, 03 medical and health sciences, 0302 clinical medicine, Osteoprotegerin, Bone Density, Internal medicine, medicine, Animals, Respiratory system, Receptor, Dental alveolus, Activator (genetics), Chemistry, lcsh:R, 030206 dentistry, General Medicine, Ligand (biochemistry), rats, Disease Models, Animal, Endocrinology, Original Article, bone mineral density, 030217 neurology & neurosurgery, receptor activator of nuclear factor-κb
Abstract

Background: Oral breathing can cause morphological changes in the oral and maxillofacial regions. Aims: To investigate whether oral breathing affected structural changes in bone tissues. Study Design: Animal experimentation. Methods: A total of 48 8-day-old male Sprague−Dawley rats were divided into two groups: a breathing group and a sham (control) group. All Sprague−Dawley rats were killed at 7 weeks after unilateral nostril obstruction modeling. Then, structural changes in bone tissues were detected by micro-computed tomography, and the expression levels of receptor activator of nuclear factor-κB, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in the signal pathway of bone metabolism within the local alveolar bone and serum of rats were detected by reverse transcription-quantitative polymerase chain reaction and Western blotting. Results: The results showed that receptor activator of nuclear factor-κB ligand and receptor activator of nuclear factor-κB levels in bone tissues and serum in the oral breathing group were higher than those in the control group [Maxillary alveolar bone: receptor activator of nuclear factor-κB ligand (pRNA=0.009, pprotein=0.008), receptor activator of nuclear factor-κB (pRNA=0.008, pprotein=0.009); Mandibular alveolar bone: receptor activator of nuclear factor-κB ligand (pRNA=0.047, pprotein=0.042), receptor activator of nuclear factor-κB (pRNA=0.041, pprotein=0.007); Serum: receptor activator of nuclear factor-κB ligand (pRNA

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results